Boston Scientific Corporation (BSX) SVP Maulik Nanavaty Sells 15,568 Shares

Boston Scientific Corporation (NYSE:BSX) SVP Maulik Nanavaty sold 15,568 shares of Boston Scientific stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $25.38, for a total value of $395,115.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Boston Scientific Corporation (NYSE:BSX) traded up $0.26 on Monday, hitting $26.18. The stock had a trading volume of 8,449,845 shares, compared to its average volume of 10,008,726. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58. The stock has a market cap of $35,590.00, a PE ratio of 374.00, a PEG ratio of 1.88 and a beta of 0.81. Boston Scientific Corporation has a fifty-two week low of $23.29 and a fifty-two week high of $29.93.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.34. The business had revenue of $2.41 billion during the quarter, compared to analysts’ expectations of $2.39 billion. Boston Scientific had a return on equity of 24.04% and a net margin of 1.15%. The business’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.30 EPS. research analysts forecast that Boston Scientific Corporation will post 1.37 EPS for the current fiscal year.

Several equities analysts have weighed in on BSX shares. Zacks Investment Research downgraded Boston Scientific from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. Canaccord Genuity started coverage on Boston Scientific in a research report on Tuesday, October 24th. They issued a “buy” rating and a $36.00 target price for the company. BMO Capital Markets lifted their target price on Boston Scientific from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Friday, October 27th. SunTrust Banks set a $34.00 target price on Boston Scientific and gave the company a “buy” rating in a research report on Tuesday, October 31st. Finally, Royal Bank of Canada reaffirmed a “buy” rating and issued a $31.00 target price on shares of Boston Scientific in a research report on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $31.00.

Institutional investors and hedge funds have recently made changes to their positions in the company. GSA Capital Partners LLP lifted its stake in Boston Scientific by 21.9% during the second quarter. GSA Capital Partners LLP now owns 12,513 shares of the medical equipment provider’s stock worth $347,000 after purchasing an additional 2,247 shares during the last quarter. Raymond James Financial Services Advisors Inc. lifted its stake in Boston Scientific by 2.7% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 44,496 shares of the medical equipment provider’s stock worth $1,233,000 after purchasing an additional 1,178 shares during the last quarter. Public Employees Retirement System of Ohio lifted its stake in Boston Scientific by 1.0% during the second quarter. Public Employees Retirement System of Ohio now owns 991,450 shares of the medical equipment provider’s stock worth $27,483,000 after purchasing an additional 10,263 shares during the last quarter. Dynamic Technology Lab Private Ltd lifted its stake in Boston Scientific by 80.8% during the second quarter. Dynamic Technology Lab Private Ltd now owns 16,800 shares of the medical equipment provider’s stock worth $466,000 after purchasing an additional 7,507 shares during the last quarter. Finally, Toronto Dominion Bank lifted its stake in Boston Scientific by 26.1% during the second quarter. Toronto Dominion Bank now owns 463,826 shares of the medical equipment provider’s stock worth $12,854,000 after purchasing an additional 95,902 shares during the last quarter. Institutional investors and hedge funds own 89.84% of the company’s stock.

WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/02/12/boston-scientific-corporation-bsx-svp-maulik-nanavaty-sells-15568-shares.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply